Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetyl-CoA carboxylase 1 and 2 are biotin-dependent enzymes serving as the first and rate-limiting step in fatty acid metabolism: ACC1 is primarily cytosolic and catalyzes de novo fatty acid synthesis by converting acetyl-CoA to malonyl-CoA in liver and adipose tissue, while ACC2 is associated with the mitochondrial outer membrane in heart and skeletal muscle and regulates fatty acid β-oxidation by controlling malonyl-CoA levels that inhibit carnitine palmitoyltransferase 1. Both isoforms are highly conserved, multi-domain enzymes regulated by phosphorylation, allosteric modulators, and oligomerization dynamics. They play vital roles in cellular energy balance, lipid storage, and are implicated as therapeutic targets in several metabolic diseases and cancer
Inhibition of fatty acid synthesis (ACC1 inhibition)\nEnhancement of fatty acid β-oxidation (ACC2 inhibition)\nInhibition of carboxylase activity\nDisruption of enzyme dimerization or conformational regulation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetyl-CoA carboxylase 1; Acetyl-CoA carboxylase 2 (ACC1; ACC2).